SKL-20540 is under clinical development by SK Life Science and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SKL-20540’s likelihood of approval (LoA) and phase transition for Cognitive Impairment Associated With Schizophrenia (CIAS) took place on 22 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SKL-20540 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SKL-20540 (SKL-15508) is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The drug candidate is administered orally. It is a small molecule that acts by targeting alpha 7-nicotinic receptor. It was under development for the treatment of Alzheimer’s disease and stable schizophrenia.
SK Life Science overview
SK Life Science (SK Life) a subsidiary of SK Biopharmaceuticals Co Ltd is a developer of medicinal products. The company develops technologies in the areas of biology and discovery, medicinal chemistry and pharmacology. Its biology and discovery research provide lead compound discovery and optimization that indentifies and validates signal and molecular targets. SK Life develops drugs for epilepsy, sleep disorder, neuropathic pain, Alzheimer’s dementia, anxiety, depression, and schizophrenia. The company’s technical expertise includes continuous flow process and chiral chemistry. It develops drugs through partnerships with universities, government organizations, pharmaceutical and biotech companies. SK Life is headquartered in Fair Lawn, New Jersey, the US.
Quick View SKL-20540 LOA Data
|Highest Development Stage|